Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. (30th June 2019)

• Record Type: Journal Article
• Authors: Khatri, Amit; Eckert, Doerthe; Oberoi, Rajneet; Suleiman, Ahmed; Pang, Yinuo; Cheng, Ling; Othman, Ahmed A.
• Is Part Of: Journal of clinical pharmacology. Volume 59:Number 12(2019)
• Page Start: 1656
• Page End: 1668
• Publication Date: 2019-06-30
• Subjects: erythrodermic psoriasis -- ethnicity -- generalized pustular psoriasis -- Japanese patients -- plaque psoriasis -- risankizumab; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1473
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Risankizumab, a humanized monoclonal antibody that targets interleukin‐23 p19 subunit, was developed for the treatment of psoriasis. This work characterizes risankizumab pharmacokinetics in Japanese and Chinese healthy subjects compared with white healthy subjects and in Japanese patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, or erythrodermic psoriasis. A phase 1, single‐dose study evaluated risankizumab pharmacokinetics and safety/tolerability in healthy white (18 and 300 mg subcutaneous [SC]), Japanese (18, 90, and 300 mg SC and 200, 600, and 1200 mg intravenous [IV]), and Chinese (18, 90, and 300 mg SC) subjects; pharmacokinetic data were analyzed using noncompartmental methods. Risankizumab pharmacokinetic data from phase 2/3 studies in Japanese patients with plaque psoriasis, generalized pustular psoriasis, or erythrodermic psoriasis following multiple SC doses of 75 mg or 150 mg were analyzed using a population pharmacokinetic approach along with data from the phase 1 and global phase 1 to 3 studies. Risankizumab plasma exposures (peak plasma concentration and area under the concentration‐time curve) were approximately dose‐proportional across 18‐ to 300‐mg SC or 200‐ to 1200‐mg IV doses. Risankizumab terminal elimination half‐life (harmonic mean 27–34 days) was comparable across doses and ethnicities. Risankizumab exposures were approximately 20% to 30% higher in Japanese and Chinese healthy subjects compared with white healthy subjects or in Japanese patients compared with non‐Japanese patients. After accounting for body‐weight differences, risankizumab exposures were comparable across ethnicities. Overall, there was no ethnic impact on risankizumab pharmacokinetics, and the small difference in exposure due to body weight has no clinical relevance.